Featured Editorial

81. 2 Key Areas To Leverage AI/ML For More Successful Clinical Trials 1/3/2023

    Artificial intelligence (AI) and machine learning (ML) can be used to minimize errors in clinical trial participant management and streamline data management. However, realizing the full potential of this technology will require overcoming issues such as data quality/access, transparency of development and validation processes, and potential data bias.

82. Two Straightforward Ways To Improve DE&I In Clinical Trials 12/27/2022

    We don’t have to wait for federal guidance, additional DHT, or new innovations. We have the tools to begin to address the lack of trust and limited data and incorporate them into diversity plans for clinical trials today. Here's how.

83. How One Pharma Company Is Embracing Digital Technologies 12/21/2022

    The increased demand for hybrid and decentralized approaches to clinical trials has increased the use of digital devices and other tools that will make studies more patient centric. Sanofi is one of the companies leading the way in getting devices into the hands of patients.

84. 4 Essential Drivers In Clinical Development For Emerging Biotechs 12/21/2022

    Enrollment, enrollment, enrollment has been the sponsor’s classic mantra for achieving success in a clinical trial. Rather, we should replace this notion with four equally essential building blocks: 1) the selection of the right CRO, 2) the identification of study sites, 3) the engagement of sites, and 4) the enrollment of patients.

85. Best Practices For Evaluating The Relevance And Quality Of RWD 12/20/2022

    Data scientists from Merck's Real-World Data Analytics and Innovation team share how they applied the Use-case specific Relevance and Quality Assessment (UReQA), a fit-for-purpose RWD quality framework, to assess and select high-quality and relevant data for RWE studies.

86. The Future Of TransCelerate: Clinical Trial Modernization 12/19/2022

    In January 2023, Janice Chang will take over as the head of industry consortia non-profit organization TransCelerate. Chang has been involved with TransCelerate since it was just a concept, and notes the time spent in the group since its launch has been an amazing journey.

87. Executives Are Eager — But Concerned — For The Future Of AI In Clinical Trials 12/14/2022

    Most life sciences execs agree that their companies — even early adopters of AI — still need to make significant changes to leverage AI properly. Here's how to get started (or keep forging ahead).

88. Boehringer Ingelheim Implements One Medicine Technology Platform 12/8/2022

    For years, Boehringer Ingelheim operated with a system comprised of best-of-breed solutions from different vendor companies. After carefully evaluating the technology environment, the company decided to move from best-of-breed solutions to an end-to-end product development platform.

89. AstraZeneca Hopes To Advance Oncology RWE 12/6/2022

    AstraZeneca is an emerging leader in the chronic lymphocytic leukemia space. It now hopes to develop treatments so patients can avoid chemotherapy, with the hope those therapies will prolong survival in patients while also producing a better quality of life.

90. What Astellas Has Learned About Decentralized Trials 11/28/2022

    When the COVID pandemic hit in the spring of 2020, many companies were unprepared for the changes that were about to impact their studies. Astellas is one company that was better prepared than most. The company had initiated a formalized, internal project on decentralized clinical trial (DCT) technologies and their use in clinical trials about nine months prior to the pandemic.